# EDGAR Filing Document

**Accession Number:** 0001421642
**File Stem:** 0001104659-26-018818
**Filing Date:** 2026-2
**Character Count:** 7745
**Document Hash:** 5708a07b4444ea4b2e06cc75865e5463
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-018818.hdr.sgml**: 20260224

**ACCESSION NUMBER**: 0001104659-26-018818

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260224

**FILED AS OF DATE**: 20260224

**DATE AS OF CHANGE**: 20260224

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Satellos Bioscience Inc.
- **CENTRAL INDEX KEY:** 0001421642
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** Z4

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43107
- **FILM NUMBER:** 26667508

**BUSINESS ADDRESS:**
- **STREET 1:** ROYAL BANK PLAZA, S. TOWER, 200 BAY ST.
- **STREET 2:** SUITE 2800
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5J 2J1
- **BUSINESS PHONE:** 416-708-0522

**MAIL ADDRESS:**
- **STREET 1:** ROYAL BANK PLAZA, S. TOWER, 200 BAY ST.
- **STREET 2:** SUITE 2800
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5J 2J1

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ICO THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20071218

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER<br> PURSUANT TO RULE 13a-16 OR 15d-16<br> OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of February 2026**

**(Commission File No. 001-43107)**

**SATELLOS BIOSCIENCE INC.**

**(Translation of registrant's name into English)**

**Royal Bank Plaza, South Tower, 200 Bay Street, Suite 2800**

**Toronto, Ontario, ON M5J 2J3**

**(Address of registrant's principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ◻ Form 40-F ⌧

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1): ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7): ◻

**DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| [99.1](tm267107d1_ex99-1.htm) | [Press release dated February 24, 2026. Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference.](tm267107d1_ex99-1.htm) |

---

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Satellos Bioscience Inc.**

---

| | |
|:---|:---|
| By: | /s/ Elizabeth Williams, CPA, CA |
| Name: | Elizabeth Williams, CPA, CA |
| Title: | Chief Financial Officer |

---

Date: February 24, 2026

## Exhibit 99.1

**Exhibit 99.1**

![](tm267107d1_ex99-1img001.jpg)

**Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference**

TORONTO, February 24, 2026 (BUSINESS WIRE) — Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida.

Oral presentations feature data from the completed Phase 1a/b study of SAT-3247 in healthy volunteers and adult patients with Duchenne muscular dystrophy (DMD), as well as new preclinical data evaluating the impact of SAT-3247 in a mouse model of facioscapulohumeral muscular dystrophy (FSHD).

**<u>Oral Presentations</u>:**

&nbsp;&nbsp;&nbsp;&nbsp;· **Abstract Title:** Assessing the impact of SAT-3247 on muscle force
in a mouse model of FSHD

&nbsp;&nbsp;&nbsp;&nbsp;· **Presenter:** Phil Lambert, PhD, Satellos Chief Scientific Officer

&nbsp;&nbsp;&nbsp;&nbsp;· **Time:** Wednesday, Mar. 11, 9:30 – 9:45 a.m. ET

&nbsp;&nbsp;&nbsp;&nbsp;· **Session:** Novel Therapeutics Approaches

&nbsp;&nbsp;&nbsp;&nbsp;· **Location:** Florida 1-3

&nbsp;&nbsp;&nbsp;&nbsp;· **Abstract Title:** A Phase 1a/b open label study of SAT-3247 in
healthy volunteers and adult patients with Duchenne Muscular Dystrophy (Poster #394 O)

&nbsp;&nbsp;&nbsp;&nbsp;· **Presenter:** Wildon Farwell, MD, MPH, Satellos Chief Medical Officer

&nbsp;&nbsp;&nbsp;&nbsp;· **Time:** Wednesday, Mar. 11, 11:30 – 11:45 a.m. ET

&nbsp;&nbsp;&nbsp;&nbsp;· **Session:** Clinical Trial Updates

&nbsp;&nbsp;&nbsp;&nbsp;· **Location:** Florida 4

**<u>Poster Presentations</u>:**

Posters sessions will take place from 10:30 a.m. – 1:30 p.m., 4 – 4:30 p.m., 6 to 8 p.m. on Tuesday, March 10 in the conference exhibit hall.

&nbsp;&nbsp;&nbsp;&nbsp;· **Title:** A Phase 1a/b open label study of SAT-3247 in healthy volunteers
and adult patients with Duchenne Muscular Dystrophy

&nbsp;&nbsp;&nbsp;&nbsp;· **Presenter:** Wildon Farwell, MD, Satellos Chief Medical Officer

&nbsp;&nbsp;&nbsp;&nbsp;· **Poster Number:** 394 O

&nbsp;&nbsp;&nbsp;&nbsp;· **Title:** TRAILHEAD: An Open-Label, Phase 2 Study Evaluating Long-Term
Safety and Efficacy of SAT-3247 in Adults with Duchenne Muscular Dystrophy (DMD)

&nbsp;&nbsp;&nbsp;&nbsp;· **Presenter:** Kristiana Salmon, Satellos Clinical Scientist

&nbsp;&nbsp;&nbsp;&nbsp;· **Poster Number:** 487 LB

&nbsp;&nbsp;&nbsp;&nbsp;· **Title:** Regenerative Index Quantitation Reveals a Reduced Regenerative
Potential in Duchenne Muscular Dystrophy from 7-11 years of age

&nbsp;&nbsp;&nbsp;&nbsp;· **Presenter:** Ryan Mitchell, PhD, Satellos Senior VP, Head of Corporate
Development

&nbsp;&nbsp;&nbsp;&nbsp;· **Poster Number:** 282 T

Full details from the scientific presentations and posters will follow in a future press release and will be available on the <u>Events and Presentations page</u> of the Satellos website.

For more information on the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, visit <u>https://www.mdaconference.org/</u>.

**ABOUT SAT-3247**

SAT-3247 is a proprietary, oral, small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle that is lost in Duchenne and other degenerative or injury conditions. Satellos is advancing SAT-3247 as a potential treatment for DMD, independent of dystrophin and regardless of exon mutation status.

**ABOUT SATELLOS BIOSCIENCE INC.**

Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of helping restore muscle stem cell signaling that is disrupted in DMD. By addressing the loss of dystrophin-dependent cues, SAT-3247 may re-establish the signals that support effective muscle regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment, initially for DMD. Satellos is also working to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit <u>www.satellos.com</u>.

**CONTACTS**

Investors: Liz Williams, CFO, <u>ir@satellos.com</u><br> Media: Emily Williams, Senior Director of Communications, <u>media@satellos.com</u>